earnings digest health care biogen idec inc biogen idec inc s revenue fell short of expectations in part on disappointing sales of avonex one of its multiple sclerosis drugs the cambridge mass biotechnology company which put itself up for sale earlier this month reported third quarter revenue rose to &# million short of the average analyst estimate of &# million according to thomson financial "the major disappointment in my view was the avonex sales which were weak in august in both the u s and some of our foreign tender markets but have rebounded nicely in september " said jim mullen biogens chief executive 
